The present analysis shows a high 2- and 3-year BRFS of 72% and 66% and a high 2- and 3-year DMFS of 79% and 66% after PSMA-PET/CT-based sENRT for such an oncologically unfavorable group of patients with PCa LN recurrence with thus a potentially second chance of cure [25]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.